0001764013-24-000046.txt : 20240404
0001764013-24-000046.hdr.sgml : 20240404
20240404162712
ACCESSION NUMBER: 0001764013-24-000046
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240402
FILED AS OF DATE: 20240404
DATE AS OF CHANGE: 20240404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Barnett Eva Renee
CENTRAL INDEX KEY: 0001883766
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38906
FILM NUMBER: 24823461
MAIL ADDRESS:
STREET 1: C/O IMMUNOVANT, INC.
STREET 2: 320 WEST 37TH STREET, 6TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunovant, Inc.
CENTRAL INDEX KEY: 0001764013
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 832771572
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: 917-580-3099
MAIL ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Health Sciences Acquisitions Corp
DATE OF NAME CHANGE: 20190108
4
1
wk-form4_1712262419.xml
FORM 4
X0508
4
2024-04-02
0
0001764013
Immunovant, Inc.
IMVT
0001883766
Barnett Eva Renee
C/O IMMUNOVANT, INC.
320 W 37TH STREET, 6TH FLOOR
NEW YORK
NY
10018
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-04-02
4
A
0
54978
0
A
375398
D
Stock Option (right to buy)
30.78
2024-04-02
4
A
0
68723
0
A
2034-04-02
Common Stock
68723
68723
D
These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
/s/ Eva Renee Barnett
2024-04-04